Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.52 |
| ▸ | HTR1A | P08908 | 8/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205356 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 | |
| SCHEMBL19205318 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 | |
| SCHEMBL19240459 | 0.99 | SLC6A2 (0.51) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 | |
| Hydrochloric Acid SCHEMBL19205314 | 0.97 | SLC6A2 (0.50) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 | |
| Hydrochloric Acid SCHEMBL19205459 | 0.97 | SLC6A2 (0.50) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 | |
| SCHEMBL19240458 | 0.97 | SLC6A2 (0.52) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 | |
| Hydrochloric Acid SCHEMBL19205346 | 0.96 | SLC6A2 (0.51) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 | |
| Hydrochloric Acid SCHEMBL19205397 | 0.96 | SLC6A2 (0.51) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 | |
| SCHEMBL5801431 | 0.84 | SLC6A2 (0.61) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 | |
| Hydrochloric Acid SCHEMBL19205421 | 0.83 | SLC6A2 (0.55) | SLC6A2SLC6A4HTR1ASLC6A3PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210971-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-3210971-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | SLC6A2 4083/4885SLC6A4 2662/4885HTR1A 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.